The EspeRare foundation today announced that Peter Potter-Lesage, former founding Chief Financial Officer of MMV - Medicines for Malaria Venture, was appointed to the foundation board, increasing the board’s size to 7 members.
“Peter has a fantastic expertise in building financial models for NGOs in drug development, we are honored to be able to benefit from this experience in the neglected diseases space to support the EspeRare’s sustainability and impact in rare diseases” commented Caroline Kant, executive director.
Peter is a member of the Board of Trustees of the Malaria Consortium (UK) and Senior Advisor for fundraising, donor relations and strategy at Medicines for Malaria Venture (MMV) in Geneva, where he previously held the position of Chief Financial Officer for 12 years. As founding CFO, he planned and executed the creation of the finance, internal control and fundraising/donor relations functions and devised financial modeling, strategy, procedures, reporting systems & financial risk management. He managed the growth of the organization from $3M to $75M per annum and coordinated with the UK government and other agencies to promote innovative financing solutions for malaria. Prior to joining MMV, Peter was a Director at UBS Investment Bank as relationship manager for Geneva International Organizations and Associate Director at SBC Warburg specializing in treasury, foreign exchange and cash management. He is a UK/Swiss national, lives in Switzerland and speaks English, French and German.
As a board member and the Treasurer, Peter will provide his expertise in financial strategy, fundraising and business development as well as risk identification and management to support the grow of Esperare’s activities in rare diseases drug development, innovative marketing strategies and health management.
